A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma

Oncologist

Volumn 12, Issue 1, 2007, Pages 114-123

  Cooley, Timothy ^a   Henry, David ^b   Tonda, Margaret ^c   Sun, Steven ^d   O'Connell, Martin ^c   Rackoff, Wayne ^d  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c ALZA CORPORATION   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

AIDS; Kaposi's sarcoma; Liposomal daunorubicin; Pegylated liposomal doxorubicin

Indexed keywords

DAUNORUBICIN; DOXORUBICIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HAND FOOT SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMAGING SYSTEM; INCIDENCE; KAPOSI SARCOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN DEFECT; THORAX PAIN; THROMBOCYTOPENIA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ASTHENIA; DOUBLE-BLIND METHOD; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; POLYETHYLENE GLYCOLS; SAFETY; SARCOMA, KAPOSI; TREATMENT OUTCOME;

EID: 33846436475     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-1-114     Document Type: Article

References (26)

1. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study. Swiss HIV Cohort Study. BMJ 1999;319:23-24.
2. Jacobson LP, Yamashita TE, Detels R et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1999;21(suppl 1):S34-S41.
3. Tam HK, Zhang ZF, Jacobson LP et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002;98:916-922.
4. Jones JL, Hanson DL, Dworkin MS et al. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000;24:270-274.
5. Buchbinder SP, Holmberg SD, Scheer S et al. Combination antiretroviral therapy and incidence of AIDS-related malignancies. J Acquir Immune Defic Syndr 1999;21(suppl 1):S23-S26.
6. Rabkin CS, Testa MA, Huang J et al. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants. J Acquir Immune Defic Syndr 1999;21(suppl 1):S31-S33.
7. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92:1823-1830.
8. Sparano JA, Anand K, Desai J et al. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. J Acquir Immune Defic Syndr 1999;21(suppl 1):S18-S22.
9. Carrieri MP, Pradier C, Piselli P et al. Reduced incidence of Kaposi's sarcoma and of systemic non-Hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer 2003;103:142-144.
10. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: Implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004;22:399-402.
11. Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 2001;42:134-139.
12. Martin-Carbonero L, Barrios A, Saballs P et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 2004;18:1737-1740.
13. Cattelan AM, Trevenzoli M, Aversa SM. Novel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma. Expert Opin Investig Drugs 2004;13:501-513.
14. Gabizon AA. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424-436.
15. Safra T, Muggia F, Jeffers S et al. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000;11:1029-1033.
16. Berry G, Billingham M, Alderman E et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998;9:711-716.
17. Hengge UR, Esser S, Rudel HP et al. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. Eur J Cancer 2001;37:878-883.
18. Nunez M, Saballs P, Valencia ME et al. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clin Trials 2001;2:429-437.
19. Newell M, Milliken S, Goldstein D et al. A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma. Aust N Z J Med 1998;28:777-783.
20. Northfelt DW, Dezube BJ, Thommes JA et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-2451.
21. Northfelt DW, Martin FJ, Working P et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996;36:55-63.
22. Osoba D, Northfelt DW, Budd DW et al. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: A randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest 2001;19:573-580.
23. Nasti G, Errante D, Santarossa S et al. A risk and benefit assessment of treatment for AIDS-related Kaposi's sarcoma. Drug Saf 1999;20:403-425.
24. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997;15:3085-3092.
25. O'Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
26. Jones RL, Berry GJ, Rubens RD et al. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol 2004;5:575-577.